Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Cholangiocarcinoma
Tucatinib and Trastuzumab in Patients With Previously Treated HER2-Positive Metastatic BTC: The SGNTUC-019 Study
Read More
Cholangiocarcinoma
Phase 2 BilT-02 Trial: Rucaparib and Nivolumab as Maintenance Therapy Following Chemotherapy in Patients With Advanced BTC
Read More
Cholangiocarcinoma
Results From the Phase 2b HERIZON-BTC-01 Study of Zanidatamab in Previously Treated HER2-Amplified BTC
Read More
Cholangiocarcinoma
Using ctDNA as a Predictive Biomarker in Patients With CCA Before and During Chemotherapy: Subanalysis of the Phase 2 STAMP Trial
Read More
Cholangiocarcinoma
Investigating Alterations in Cancer Driver Genes and Other Mutations in Patients With Intrahepatic CCA: Phase 3 BILCAP Trial
Read More
Cholangiocarcinoma
Using Liquid Biopsy to Detect FGFR2 and Other Actionable Rearrangements in GI Malignancies
Read More
Cholangiocarcinoma
BI 907828, an MDM2-p53 Antagonist, Demonstrated Promising Efficacy in Patients With Advanced BTC
Read More
Cholangiocarcinoma
Patients With Advanced BTC Treated With CTX-009 Plus Paclitaxel in a Phase 2 Study
Read More
Cholangiocarcinoma
The Use of Gunagratinib in Patients With Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements: A Phase 2 Study
Read More
Cholangiocarcinoma
GemCis and Nab-Paclitaxel Versus GemCis in Advanced BTC: Results From the SWOG 1815 Study
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 27
